Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial

Single low doses of primaquine, when added to artemisinin-based combination therapy, might prevent transmission of Plasmodium falciparum malaria to mosquitoes. A single dose of 0·25 mg/kg primaquine, given alongside dihydroartemisinin–piperaquine, was safe and efficacious for the prevention of P falciparum malaria transmission in boys and men who are not deficient in G6PD

Author: , , , , , , , , , , , , , , , , , , ,
Publication date: June 2016
Source: The Lancet Infectious Diseases

Past and new challenges for malaria control and elimination: the role of operational research for innovation in designing interventions

This meeting report presents the outcomes of a workshop held in Bangkok on December 1st 2014, where the following challenges were discussed: the threat of resistance to artemisinin and artemisinin-based combination therapy in the Greater Mekong Sub-region (GMS) and in Africa; access to treatment for most at risk and hard to reach population; insecticide resistance, residual and outdoors transmission.

Author: , , , , , , , , , ,
Publication date: July 2015

Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker

Emergence of artemisinin resistance in Southeast Asia poses a serious threat to the global control of Plasmodium falciparum malaria. Currently, artemisinin resistance extends across much of Myanmar. P falciparum parasites carrying K13-propeller mutations were recorded at high prevalence next to the northwestern border with India. Appropriate therapeutic regimens should be tested urgently and implemented comprehensively if spread of artemisinin resistance to other regions is to be avoided.

Author: , , , , , , , , , , , , , , , , , , , , , , , , , ,
Publication date: February 2015
Source: The Lancet Infectious Diseases